2 Reasons to Buy Biogen, 1 Reason to Sell
Biogen (NASDAQ: BIIB) offered investors a huge win last year when regulators approved Aduhelm -- its controversial Alzheimer's treatment. The stock soared 52% in just a few days.
But the road hasn't been easy since. Many neurologists have refused to prescribe the medication. And the Centers for Medicare and Medicaid Services recently said it would limit coverage of the medication to those patients in clinical trials. Biogen shares have slipped more than 45% from that high point reached last June.
To make matters worse, Biogen faces declines in its top-selling medications. The reason? Generic competition is eating away at market share. In this context, is Biogen an absolute sell? Maybe not. There are often a few ways to look at a picture. And here, there are two reasons to buy Biogen stock now -- and one reason to sell.
Source Fool.com
